Skip to main content
JCR Pharmaceuticals Co.,Ltd. logo

JCR Pharmaceuticals Co.,Ltd. — Investor Relations & Filings

Ticker · 4552 ISIN · JP3701000006 LEI · 353800IMIU9CQ1DGOS14 T Manufacturing
Open in API
Filings indexed 62 across all filing types
Latest filing 2022-08-10 Interim / Quarterly Rep…
Country JP Japan
Listing T 4552

About JCR Pharmaceuticals Co.,Ltd.

https://www.jcrpharm.co.jp/en/site/en/

JCR Pharmaceuticals is a global specialty biopharmaceutical company focused on the research, development, manufacturing, and commercialization of treatments for rare and genetic diseases. The company's portfolio includes therapies for conditions such as growth disorders, Mucopolysaccharidosis II (Hunter syndrome), and Fabry disease. A primary area of innovation involves developing treatments for central nervous system (CNS) disorders by utilizing proprietary technology to deliver biotherapeutics across the blood-brain barrier. JCR also develops and sells regenerative medicine products, aiming to address complex healthcare challenges and provide new treatment options for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
四半期報告書－第48期第1四半期(令和4年4月1日－令和4年6月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed by JCR Pharmaceuticals Co., Ltd. with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains comprehensive financial statements, including the balance sheet, income statement, and comprehensive income statement for the first quarter of the 48th fiscal year (April 1, 2022, to June 30, 2022). It also includes management's analysis of financial results and business conditions. This fits the definition of an Interim/Quarterly Report (IR). Q1 2023
2022-08-10 Japanese
確認書
Audit Report / Information Classification · 98% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act in Japan, which accompanies the Annual Securities Report (Yukashoken Hokokusho). Since it is a regulatory filing confirming the accuracy of the annual report and does not contain the full financial report itself, it falls under the category of general regulatory filings. FY 2022
2022-06-22 Japanese
内部統制報告書－第47期(令和3年4月1日－令和4年3月31日)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act (金融商品取引法). This is a specific regulatory requirement in Japan that accompanies the annual financial statements to attest to the effectiveness of internal controls over financial reporting. Since it is a standalone regulatory filing regarding internal control assessment and does not fit into the other specific categories like 10-K or IR, it is best classified as a Regulatory Filing (RNS).
2022-06-22 Japanese
有価証券報告書－第47期(令和3年4月1日－令和4年3月31日)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains the standard cover page with the company name (JCR Pharmaceuticals), the fiscal year (47th period, 2021-04-01 to 2022-03-31), and extensive XBRL tagging data typical of a full annual financial filing submitted to the Kanto Local Finance Bureau. FY 2022
2022-06-22 Japanese
四半期報告書－第47期第3四半期(令和3年10月1日－令和3年12月31日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for JCR Pharmaceuticals Co., Ltd., covering the third quarter of the 47th fiscal year (period ending December 31, 2021). It contains detailed financial statements, including the balance sheet, income statement, and comprehensive income statement, as well as management analysis and notes. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-02-14 Japanese
四半期報告書－第47期第2四半期(令和3年7月1日－令和3年9月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for JCR Pharmaceuticals Co., Ltd., covering the second quarter of the 47th fiscal year (July 1, 2021, to September 30, 2021). It contains detailed financial statements, management analysis (MDA), and corporate information as required by the Financial Instruments and Exchange Act of Japan. Since it is a comprehensive financial report for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). Q2 2022
2021-11-12 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.